Clinical Trials With
TheraSphere® YTTRIUM-90 GLASS MICROSPHERES

Did You Know:
Liver Cancer is the fifth-most-common cancer in men and the ninth-most-common cancer in women.10

EPOCH

Protocol TS-102 / NCT01483027
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in patients with metastatic colorectal carcinoma of the liver who have failed first-line chemotherapy

STOP-HCC

Protocol TS-103 / NCT01556490
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) in the treatment of patients with unresectable hepatocellular carcinoma (HCC)

YES-P

Protocol TS-104 / NCT01887717
Evaluating yttrium-90 trans-arterial radioembolization (TheraSphere®) versus the standard of care (sorafenib) for the treatment of advanced HCC with portal vein thrombosis

CAUTION - Investigational Device.
Limited by United States law to investigational use.